Join
Live feed
·
PRReleasevia Quantisnow
Arvinas Inc. logo

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

ByQuantisnow·Wall Street's wire, on your screen.
ARVN· Arvinas Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARVN (Arvinas Inc.) and more on Quantisnow.